Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
August 17, 2017AgeX Therapeutics Closes $10 Million Capital Raise
• BioTime saving approximately $5 million annually on programs now in AgeXALAMEDA, Calif.--(BUSINESS WIRE)-- AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE American: BTX), announced today that it has closed its round of equity financing, raising net proceeds of $10 million, valuing AgeX at approximately $68 million post-money. Post-closing, BioTime owns approximately 85% of the outstanding shares of AgeX. The financing, first announced on August 2, 2017, is expected to fund ... 
Printer Friendly Version
August 14, 2017BioTime Announces $2 Million Grant for Further Development of OpRegen® for Dry-AMD
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 14, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, has been awarded a new grant for 2017 of up to 7.2 million Israeli New Shekels (approximately $2 million) from the Israel Innovation Authority (the “IIA”). The grant provides funding for the continued development of OpRegen®, and to date the IIA has prov... 
Printer Friendly Version
August 09, 2017AgeX Therapeutics CEO Michael D. West, Ph.D. to Deliver Keynote Address on Biotechnology and Aging at RAAD Festival
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 9, 2017-- AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE MKT:BTX), announced today that CEO Michael D. West, Ph.D., will deliver the keynote presentation at the RAAD Festival 2017 (RAADfest), a large annual gathering of life extension experts, August 9-13, at the Town and Country Resort & Convention Center in San Diego, California. Dr. West will deliver the presentation titled “Telome... 
Printer Friendly Version
August 02, 2017BioTime Reports Second Quarter Results and Recent Corporate Accomplishments
Conference Call and Live Webcast 4.30pm Eastern Time Today ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 2, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today reported financial results for the second quarter ended June 30, 2017. “The second quarter of 2017 was very productive for BioTime, with numerous significant clinical, financial and... 
Printer Friendly Version
August 02, 2017AgeX Therapeutics Obtains $10 Million in Capital and Commences Operations
Leverages Intellectual Property Assets from the BioTime Group of Companies Relating to Cellular Immortality and Regenerative Biology Funding to Advance the Development of Products Targeting Large Markets Associated with Age-Related Disease ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 2, 2017-- AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE MKT: BTX), today reported that it has successfully raised $10 million in equity financing to fund its operations. Following... 
Printer Friendly Version
July 25, 2017BioTime Receives DSMB Approval to Start Third Patient Cohort in Clinical Trial for Dry-AMD; Commences Patient Enrollment in the US
ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 25, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that the Data Safety Monitoring Board (DSMB) has authorized the Company to move forward with enrollment for cohort 3. The DSMB is an independent group of medical experts closely monitoring the Phase I/IIa OpRegen® clinical trial. In cohort 3 BioTim... 
Printer Friendly Version
July 20, 2017BioTime, Inc. to Announce Second Quarter 2017 Results on August 2, 2017
Conference Call and Webcast on Wednesday, August 2, 2017, at 4:30 p.m. ET / 1:30 p.m. PT ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 20, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will release second quarter financial and operating results on Wednesday, August 2, 2017, after the close of the U.S. financial markets. The... 
Printer Friendly Version
July 19, 2017Data From BioTime’s Phase I/IIa OpRegen® Trial to be Presented at the 2017 American Academy of Ophthalmology (AAO) Annual Meeting
ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 19, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that an abstract related to the Company’s retinal tissue implant has been accepted for a paper presentation at the American Academy of Ophthalmology (AAO) annual meeting being held in New Orleans, Louisiana, November 11-14. The abstr... 
Printer Friendly Version
July 18, 2017BioTime to Host Key Opinion Leader Event on the Topic of Dry AMD in New York City
Live Webcast at 12 noon EDT on Tuesday, July 25 ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 18, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, announced today that it will host a Key Opinion Leader event on the topic of dry age-related macular degeneration (AMD) in New York City on Tuesday, July 25. The meeting will feature a presentation by key ... 
Printer Friendly Version
July 13, 2017BioTime Subsidiary AgeX Therapeutics Appoints Aubrey de Grey, Ph.D. as VP of New Technology Discovery
World-Renowned Aging Researcher and Biomedical Gerontologist to Lead AgeX’s Research ALAMEDA, Calif. & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Jul. 13, 2017-- AgeX Therapeutics (“AgeX”), a subsidiary of BioTime, Inc. (NYSE MKT:BTX) with a focus on developing new therapies in the field of biomedical gerontology, today announced the appointment of distinguished researcher and advocate Aubrey de Grey, Ph.D. as Vice-President of New Technology ... 
Printer Friendly Version
June 19, 2017Hadasit Bio-Holdings (HBL) and BioTime Complete Shares Swap Transaction in Cellcure Neurosciences
As part of the transaction, HBL, which owns 21% of Cellcure's share capital, will sell its entire holdings to BioTime, Inc., In exchange, BioTime will pay $12.75 million in Biotime shares to HBL JERUSALEM, June 19, 2017 /PRNewswire/ -- Hadasit Bio-Holdings Ltd. ("HBL") (TASE: HDST) announced that it has completed a share swap transaction with BioTime, Inc., ("BioTime") (TASE: BTX.TA) in their joint portfolio company Cell Cure Neurosciences ("Cell Cure"). The transaction is the first exi... 
Printer Friendly Version
June 19, 2017BioTime Expands & Advances Ophthalmology Portfolio
Expanded Exclusive, Global License to RPE and Photoreceptor Cells for Use in All Eye Disorders Data Presented at International Society for Stem Cell Research (ISSCR) Conference Translational Vision Sciences & Technology (TVST) Journal Publishes OpRegen® Data ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 19, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing ... 
Printer Friendly Version
June 14, 2017BioTime’s Renevia® Achieves Primary Endpoint in European Pivotal Trial
• Data Reinforce Renevia’s Potential in Multi-Billion Dollar Facial Aesthetics Market • BioTime on Track to File for Renevia CE Mark by End of 2017 • Conference Call Today with Lead Investigator at 4:30 p.m. ET ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 14, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today reported that... 
Printer Friendly Version
June 08, 2017BioTime to Announce Top Line Data From the Company’s Renevia European Pivotal trial
Schedules Conference Call for 4:30pm ET on June 14, 2017 ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 8, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will report the top line data from the Company’s Renevia European pivotal trial, before the US market open on Wednesday, June 14, 2017. The Company will host a conference call and ... 
Printer Friendly Version
May 23, 2017BioTime Co-CEO Dr. Michael West to Deliver Presentation as Part of Biotech Panel at Mauldin Economics’ Strategic Investment Conference on May 24
ALAMEDA, Calif.--(BUSINESS WIRE)--May 23, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer Michael D. West, Ph.D., is delivering a presentation as part of a panel on biotechnology at the Mauldin Economics’ Strategic Investment Conference on Wednesday, May 24 at 3:20pm EDT at the Omni Orlando Resort i... 
Printer Friendly Version
May 23, 2017BioTime to Present at 16th National Life Sciences and Biotechnology Week (MIXiii BIOMED)
ALAMEDA, Calif.--(BUSINESS WIRE)--May 23, 2017-- BioTime, Inc. (NYSE MKT: BTX and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that BioTime, and its subsidiary Cell Cure Neurosciences Ltd., will be featured in two presentations at the 16th National Life Sciences and Biotechnology Week (MIXiii BIOMED) on Wednesday, May 24, 2017 as part of the Regenerative ... 
Printer Friendly Version
May 11, 2017BioTime Presents Retinal Restoration Data at ARVO
Demonstrates Ability to Grow Full-Thickness, 3-D Retinal Tissue Tissue is Highly Similar to Natural Human Tissue ALAMEDA, Calif.--(BUSINESS WIRE)--May 11, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that a poster related to the Company’s retinal restoration technology was presented at the Annual Meeting of the Asso... 
Printer Friendly Version
May 10, 2017BioTime, Inc. Reports First Quarter Results and Recent Corporate Accomplishments
Conference Call and Webcast Today at 4:30 p.m. Eastern Time ALAMEDA, Calif--(BUSINESS WIRE)--May 10, 2017-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today reported financial results for the first quarter ended March 31, 2017. “At BioTime we are continuing to make meaningful clinical progress with our core development programs... 
Printer Friendly Version
May 09, 2017BioTime Announces New Positive Data from OpRegen® Trial in Dry-AMD
Imaging Analysis Suggests Cell Engraftment and Likely Biological Response ALAMEDA, Calif.--(BUSINESS WIRE)--May 9, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced new data from the Phase I/IIa clinical trial of OpRegen® in the advanced form of dry age-related macular degeneration (dry-AMD). The interim data were presented on May ... 
Printer Friendly Version
May 08, 2017BioTime Co-CEO Dr. Michael D. West to Present at World Advanced Therapies & Regenerative Medicine Congress on May 17 and 19
Dr. West to Deliver Presentation on Applying AI to Stem Cell Biology and Participate in Roundtable Discussion ALAMEDA, Calif.--(BUSINESS WIRE)--May 8, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer Michael D. West, Ph.D. will present at Terrapinn’s World Advanced Therapies & Regenerative Me... 
Printer Friendly Version
April 26, 2017BioTime, Inc. to Announce First Quarter 2017 Results on May 10, 2017
Conference Call and Webcast on Wednesday, May 10, 2017, at 4:30 p.m. ET / 1:30 p.m. PT ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 26, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will release first quarter financial and operating results on Wednesday, May 10, 2017, after the close of the U.S. financial markets. The Compa... 
Printer Friendly Version
April 24, 2017BioTime to Present Additional Data at Upcoming ARVO
Retinal tissue regeneration presentation added OpRegen® presentation scheduled for May 8 ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 24, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that an abstract related to the Company’s retinal tissue implant has been accepted for a paper presentation at the Annual Meeting of ... 
Printer Friendly Version
April 06, 2017BioTime Forms New Subsidiary AgeX Therapeutics, Inc. to Develop its Programs Focused on Human Aging
Objective is to quickly establish leadership in the emerging biotechnology field of Aging through pluripotency and iTR™ assets BioTime continues execution of corporate simplification strategy while remaining focused on Ophthalmology, Aesthetics and Therapeutics Delivery ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 6, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing... 
Printer Friendly Version
April 04, 2017BioTime Co-CEO Dr. Michael West to Deliver Keynote Presentation at GTC Bio Stem Cell Summit on April 6
Will Present on the Promise of Pluripotent Cells in Advanced Therapeutics and the Company’s Plans to Develop Applications in Human Aging ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 4, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer Michael D. West, Ph.D., is delivering a keynote presentation at the GT... 
Printer Friendly Version
March 28, 2017Key BioTime Patents Upheld by European Patent Office
EPO Rules Patents for OpRegen® are Valid and Remain in Force as Granted OpRegen® is in Development to Treat Dry-AMD ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 28, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical stage biotechnology company developing and commercializing products addressing degenerative disease, today announced the successful defense of two key patents from challenge before the European Patent Office (EPO) Opposition divisio... 
Printer Friendly Version
March 20, 2017BioTime to Present at Oppenheimer 27th Annual Healthcare Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 20, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer, will be presenting at the Oppenheimer 27th Annual Healthcare Conference at the Westin Grand Central in New York City on March 21, at 3:55 p.m. Eastern Time. A webcast of Mr. Skibsted’s ... 
Printer Friendly Version
March 16, 2017BioTime, Inc. Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Accomplishments
Conference Call and Webcast Today at 4:30 p.m. Eastern Time ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 16, 2017-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today reported financial results for the fourth quarter and year ended December 31, 2016. “I’m happy with the tremendous progress we made last year in all three of our strategi... 
Printer Friendly Version
March 15, 2017Data From BioTime’s OpRegen® Trial in Dry-AMD to be Presented at ARVO on May 8
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 15, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that a poster presentation based on data from its Phase I/IIa clinical trial of OpRegen® in the advanced form of dry age-related macular degeneration (dry-AMD) will be presented at the Annual Meeting of the Association for Research in Vision ... 
Printer Friendly Version
March 13, 2017BioTime Expands OpRegen® Clinical Trial in Dry-AMD With Opening of First US Sites
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 13, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the expansion of its ongoing Phase I/IIa clinical trial for OpRegen® in the advanced dry form age-related macular degeneration (dry-AMD) by naming the first two sites that will treat patients in the U.S. “The addition of U.S. clinical... 
Printer Friendly Version
February 23, 2017BioTime, Inc. to Announce Fourth Quarter and Fiscal 2016 Results on March 16, 2017
ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 23, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will release fourth quarter and fiscal 2016 financial and operating results on Thursday, March 16, 2017, after the close of the U.S. financial markets. The Company will host a conference call and webcast on Thursday, March 16, 2017, at 4:30 ... 
Printer Friendly Version
February 21, 2017BioTime Reports Pro Forma Gain on Deconsolidation of OncoCyte Subsidiary
ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 21, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the deconsolidation of OncoCyte Inc.’s financial statements from BioTime’s consolidated financial statements effective February 17, 2017. As a result of the deconsolidation, BioTime will report a pro forma, non-cash gain of approximately $56 million... 
Printer Friendly Version
February 15, 2017BioTime, Inc. Announces Closing of Public Offering of Common Stock
ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Feb. 15, 2017-- BioTime, Inc. (NYSE MKT and TASE:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the closing of its previously announced underwritten public offering. BioTime, Inc. sold 7,453,704, shares of its common stock in the offering, which includes 972,222 shares of its common stock issued in connection with the ... 
Printer Friendly Version
February 15, 2017CORRECTING and REPLACING BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement for Next-Generation Retinal Disease Therapy From University of Pittsburgh
Advanced retinal regeneration program could lead to fully functional retinal tissue implants to restore vision in late stages of blindness ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 15, 2017-- Please replace the release dated February 6, 2017, with the following corrected version due to multiple revisions. The corrected release reads: BIOTIME EXPANDS OPHTHALMOLOGY PORTFOLIO WITH GLOBAL IN-LICENSING AGREEMENT FOR NEXT-GENERATION RET... 
Printer Friendly Version
February 13, 2017BioTime to Present at Two Upcoming Investor Conferences
ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 13, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer, will be presenting at the BIO CEO & Investor Conference at the Waldorf-Astoria Hotel in New York City on Tuesday, February 14, at 2:30 p.m. Eastern Time, and at the Disruptive Growth Confer... 
Printer Friendly Version
February 10, 2017BioTime, Inc. Announces Pricing of Public Offering of Common Stock
ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Feb. 10, 2017-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the pricing of an underwritten public offering of 6,481,482 shares of its common stock at a public offering price of $2.70 per share. The gross proceeds to BioTime, Inc. from this offering are expected to be approximately $... 
Printer Friendly Version
February 09, 2017BioTime, Inc. Announces Proposed Public Offering of Common Stock
ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Feb. 9, 2017-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced its intent to offer to sell shares of its common stock in an underwritten public offering. BioTime, Inc. also expects to grant to the underwriters for the offering a 30-day option to purchase up to an additional 15% of the n... 
Printer Friendly Version
February 07, 2017BioTime Appoints Industry Veteran, Stephana Patton, Ph.D., J.D., as General Counsel
Draws on a Deep Background at Leading Life Sciences Companies ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 7, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the appointment of Stephana Patton, Ph.D., J.D., as General Counsel, a newly created position. Reporting in her new role to Adi Mohanty, Co-CEO, Dr. Patton will oversee ... 
Printer Friendly Version
February 06, 2017BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement for Next-Generation Retinal Disease Therapy From University of Pittsburgh Medical Center
Advanced retinal regeneration program could lead to fully functional retinal tissue implants to restore vision in late stages of blindness ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 6, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the acquisition of global rights to ophthalmology-related intellectual property (IP) assets from the Univer... 
Printer Friendly Version
January 26, 2017BioTime to Present at Noble Capital Markets’ Thirteenth Annual Investor Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 26, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that management will present a corporate overview at the NobleCon13 - Noble Capital Markets’ Thirteenth Annual Investor Conference at the Boca Raton Resort & Club in Boca Raton, Florida, on Monday, January 30, at 11:00 a.m. Eastern Standard Tim... 
Printer Friendly Version
January 19, 2017Additional Data From BioTime’s OpRegen® Clinical Trial in Dry-AMD to be Presented at ARVO 2017
-Data from patients in Cohort 1 and Cohort 2 to be presented- ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 19, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical stage biotechnology company with a focus on pluripotent stem cell technologies, and its subsidiary, Cell Cure Neurosciences, Ltd., today announced that an abstract evaluating OpRegen® in patients with advanced dry Age-Related Macular Degeneration (dry-AMD) based on the ongoing Phase I/IIa clinical tr... 
Printer Friendly Version
January 03, 2017BioTime and Subsidiary Cell Cure Neurosciences Establish Innovative Cell Therapy Manufacturing Center in Jerusalem, Israel
-Supplying OpRegen® for the Ongoing Clinical Trial for the Treatment of Dry Age-Related Macular Degeneration- -Center has Capability to Manufacture Additional BioTime Products- ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Jan. 3, 2017-- BioTime, Inc. (NYSE MKT: BTX and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, and its majority-owned subsidiary, Cel... 
Printer Friendly Version